Display options
Cite
Decker C, Yu ZF, Giugliani R, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: Growth and pubertal development in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase. J Pediatr Rehabil Med. 2010;3(2):89-100doi: 10.3233/PRM-2010-0113.
Decker, C., Yu, Z. F., Giugliani, R., Schwartz, I. V., Guffon, N., Teles, E. L., Miranda, M. C., Wraith, J. E., Beck, M., Arash, L., Scarpa, M., Ketteridge, D., Hopwood, J. J., Plecko, B., Steiner, R., Whitley, C. B., Kaplan, P., Swiedler, S. J., Conrad, S., & Harmatz, P. (2010). Enzyme replacement therapy for mucopolysaccharidosis VI: Growth and pubertal development in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase. Journal of pediatric rehabilitation medicine, 3(2), 89-100. https://doi.org/10.3233/PRM-2010-0113
Decker, Celeste, et al. "Enzyme replacement therapy for mucopolysaccharidosis VI: Growth and pubertal development in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase." Journal of pediatric rehabilitation medicine vol. 3,2 (2010): 89-100. doi: https://doi.org/10.3233/PRM-2010-0113
Decker C, Yu ZF, Giugliani R, Schwartz IV, Guffon N, Teles EL, Miranda MC, Wraith JE, Beck M, Arash L, Scarpa M, Ketteridge D, Hopwood JJ, Plecko B, Steiner R, Whitley CB, Kaplan P, Swiedler SJ, Conrad S, Harmatz P. Enzyme replacement therapy for mucopolysaccharidosis VI: Growth and pubertal development in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase. J Pediatr Rehabil Med. 2010;3(2):89-100. doi: 10.3233/PRM-2010-0113. PMID: 20634905; PMCID: PMC2904323.
Copy Download .nbib Format: NLM
Share it on

J Pediatr Rehabil Med. 2010;3(2):89-100. doi: 10.3233/PRM-2010-0113.

Enzyme replacement therapy for mucopolysaccharidosis VI: Growth and pubertal development in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase.

Journal of pediatric rehabilitation medicine

Celeste Decker, Zi-Fan Yu, Roberto Giugliani, Ida Vanessa D Schwartz, Nathalie Guffon, Elisa Leão Teles, M Clara Sá Miranda, J Edmond Wraith, Michael Beck, Laila Arash, Maurizio Scarpa, David Ketteridge, John J Hopwood, Barbara Plecko, Robert Steiner, Chester B Whitley, Paige Kaplan, Stuart J Swiedler, Susan Conrad, Paul Harmatz

Affiliations

  1. BioMarin Pharmaceutical Inc, Novato, CA, USA.

PMID: 20634905 PMCID: PMC2904323 DOI: 10.3233/PRM-2010-0113

Abstract

BACKGROUND AND METHODS: Growth failure is characteristic of untreated mucopolysaccharidosis type VI (MPS VI: Maroteaux-Lamy syndrome). Growth was studied in fifty-six MPS VI patients (5 to 29 years old) prior to and for up to 240 weeks of weekly infusions of recombinant human arylsulfatase B (rhASB) at 1 mg/kg during Phase 1/2, Phase 2, Phase 3 or Phase 3 Extension clinical trials. Height, weight, and Tanner stage data were collected. Pooled data were analyzed to determine mean height increase by treatment week, growth impacts of pubertal status, baseline urinary GAG, and age at treatment initiation. Growth rate for approximately 2 years prior to and following treatment initiation was analyzed using longitudinal modeling. RESULTS: Mean height increased by 2.9 cm after 48 weeks and 4.3 cm after 96 weeks on enzyme replacement therapy (ERT). Growth on ERT was not correlated with baseline urinary GAG. Patients under 16 years of age showed greatest increases in height on treatment. Model results based on pooled data showed significant improvement in growth rate during 96 weeks of ERT when compared to the equivalent pretreatment time period. Delayed pubertal onset or progression was noted in 10 patients entering the clinical trials; all of whom showed progression of at least one Tanner stage during 2 years on ERT, and 6 of whom (60%) completed puberty. CONCLUSION: Analysis of mean height by treatment week and longitudinal modeling demonstrate significant increase in height and growth rate in MPS VI patients receiving long-term ERT. This impact was greatest in patients aged below 16 years. Height increase may result from bone growth and/or reduction in joint contractures. Bone growth and resolution of delayed puberty may be related to improvements in general health, bone cell health, nutrition, endocrine gland function and reduced inflammation.

References

  1. Pediatrics. 2009 Jan;123(1):229-40 - PubMed
  2. Am J Clin Nutr. 1979 Mar;32(3):607-29 - PubMed
  3. Pediatrics. 2005 Jun;115(6):e681-9 - PubMed
  4. Arch Dis Child. 1969 Jun;44(235):291-303 - PubMed
  5. Eur J Med Genet. 2008 Sep-Oct;51(5):466-71 - PubMed
  6. Bone Marrow Transplant. 2008 Jun;41(12):1005-11 - PubMed
  7. J Pediatr. 2004 May;144(5):574-80 - PubMed
  8. Acta Paediatr Scand Suppl. 1989;356:26-37 - PubMed
  9. J Pediatr. 2006 Apr;148(4):533-539 - PubMed
  10. Acta Paediatr Scand Suppl. 1989;350:70-94 - PubMed
  11. Pediatrics. 1998 Aug;102(2 Pt 3):507-11 - PubMed
  12. Rev Hosp Clin Fac Med Sao Paulo. 1991 Jan-Feb;46(1):9-13 - PubMed
  13. Am J Pathol. 2008 Jan;172(1):112-22 - PubMed
  14. Am J Med Genet A. 2005 Apr 15;134A(2):144-50 - PubMed
  15. Arch Pediatr Adolesc Med. 1995 Jun;149(6):658-62 - PubMed
  16. Bone. 1997 Nov;21(5):425-31 - PubMed
  17. Pediatrics. 2007 Aug;120(2):405-18 - PubMed
  18. Am J Med Genet A. 2008 May 15;146A(10):1286-95 - PubMed
  19. Mol Genet Metab. 2007 Feb;90(2):171-80 - PubMed
  20. Lab Invest. 2001 Sep;81(9):1319-28 - PubMed
  21. Arch Dis Child. 1970 Feb;45(239):13-23 - PubMed
  22. Pediatrics. 2008 Feb;121 Suppl 3:S172-91 - PubMed
  23. Eur J Pediatr. 2004 Jun;163(6):323-6 - PubMed
  24. J Pediatr Endocrinol Metab. 1995 Oct-Dec;8(4):305-7 - PubMed
  25. J Med Genet. 1989 Nov;26(11):731-2 - PubMed
  26. Am J Clin Nutr. 2008 Aug;88(2):364-71 - PubMed
  27. J Pediatr. 1985 Sep;107(3):317-29 - PubMed
  28. Mol Genet Metab. 2008 Aug;94(4):469-75 - PubMed
  29. Pediatr Res. 2005 May;57(5 Pt 1):701-7 - PubMed

Publication Types

Grant support